JPWO2020072324A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020072324A5 JPWO2020072324A5 JP2021542068A JP2021542068A JPWO2020072324A5 JP WO2020072324 A5 JPWO2020072324 A5 JP WO2020072324A5 JP 2021542068 A JP2021542068 A JP 2021542068A JP 2021542068 A JP2021542068 A JP 2021542068A JP WO2020072324 A5 JPWO2020072324 A5 JP WO2020072324A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- lipid
- compound
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000002632 lipids Chemical class 0.000 claims 18
- 239000002245 particle Substances 0.000 claims 11
- -1 poly(oxazoline) Polymers 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 108020004459 Small interfering RNA Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 108700011259 MicroRNAs Proteins 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 239000002924 silencing RNA Substances 0.000 claims 3
- 229930182558 Sterol Natural products 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920002187 poly[N-2-(hydroxypropyl) methacrylamide] polymer Polymers 0.000 claims 1
- 229920000223 polyglycerol Polymers 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000009452 underexpressoin Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023193747A JP7747712B2 (ja) | 2018-10-01 | 2023-11-14 | 活性物質の送達のための生分解性脂質 |
| JP2025155219A JP2026009116A (ja) | 2018-10-01 | 2025-09-18 | 活性物質の送達のための生分解性脂質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739548P | 2018-10-01 | 2018-10-01 | |
| US62/739,548 | 2018-10-01 | ||
| PCT/US2019/053617 WO2020072324A1 (en) | 2018-10-01 | 2019-09-27 | Biodegradable lipids for the delivery of active agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023193747A Division JP7747712B2 (ja) | 2018-10-01 | 2023-11-14 | 活性物質の送達のための生分解性脂質 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022508511A JP2022508511A (ja) | 2022-01-19 |
| JP2022508511A5 JP2022508511A5 (https=) | 2022-08-01 |
| JPWO2020072324A5 true JPWO2020072324A5 (https=) | 2022-08-01 |
| JP7387745B2 JP7387745B2 (ja) | 2023-11-28 |
Family
ID=68281954
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542068A Active JP7387745B2 (ja) | 2018-10-01 | 2019-09-27 | 活性物質の送達のための生分解性脂質 |
| JP2023193747A Active JP7747712B2 (ja) | 2018-10-01 | 2023-11-14 | 活性物質の送達のための生分解性脂質 |
| JP2025155219A Pending JP2026009116A (ja) | 2018-10-01 | 2025-09-18 | 活性物質の送達のための生分解性脂質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023193747A Active JP7747712B2 (ja) | 2018-10-01 | 2023-11-14 | 活性物質の送達のための生分解性脂質 |
| JP2025155219A Pending JP2026009116A (ja) | 2018-10-01 | 2025-09-18 | 活性物質の送達のための生分解性脂質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220370356A1 (https=) |
| EP (3) | EP4635481A3 (https=) |
| JP (3) | JP7387745B2 (https=) |
| KR (2) | KR20260003834A (https=) |
| CN (2) | CN113164379B (https=) |
| AU (2) | AU2019351809C1 (https=) |
| CA (1) | CA3114435A1 (https=) |
| DK (2) | DK3860561T3 (https=) |
| ES (2) | ES3046484T3 (https=) |
| WO (1) | WO2020072324A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6997862B2 (ja) | 2018-08-21 | 2022-02-10 | 株式会社東芝 | 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット |
| ES3046484T3 (en) * | 2018-10-01 | 2025-12-02 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| WO2020219876A1 (en) * | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| US20240050378A1 (en) * | 2020-12-02 | 2024-02-15 | Merck Sharp & Dohme Llc | Lipid nanoparticle compositions containing monoester cationic lipids |
| WO2022155728A1 (en) * | 2021-01-19 | 2022-07-28 | The University Of British Columbia | Sulfur-containing lipids |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN115010681A (zh) * | 2021-09-07 | 2022-09-06 | 安徽荣灿生物科技有限公司 | 一类阳离子脂质体分子及其制备和应用 |
| CN115894281B (zh) * | 2021-09-22 | 2025-07-01 | 广州谷森制药有限公司 | 阳离子脂质化合物、其制备方法、组合物及应用 |
| AR127312A1 (es) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
| CN114409554A (zh) * | 2022-01-27 | 2022-04-29 | 英维沃生物科技(苏州)有限公司 | 一种新型阳离子脂质化合物及其组合物和用途 |
| CN119654166A (zh) | 2022-04-01 | 2025-03-18 | 内诺维什疗法股份有限公司 | mRNA递送方法及其组合物 |
| CN117003808A (zh) * | 2022-04-28 | 2023-11-07 | 北京科兴中维生物技术有限公司 | 一种阳离子脂质化合物及其制备方法和用途 |
| CN116969851A (zh) | 2022-04-29 | 2023-10-31 | 北京剂泰医药科技有限公司 | 可电离脂质化合物 |
| CN115887674B (zh) * | 2022-04-29 | 2023-08-25 | 北京剂泰医药科技有限公司 | 脂质纳米颗粒 |
| CN117263818A (zh) * | 2022-06-14 | 2023-12-22 | 杭州高田生物医药有限公司 | 阳离子脂质化合物及其制备方法和应用 |
| KR20250094676A (ko) * | 2022-10-25 | 2025-06-25 | 나노베이션 테라퓨틱스 인크. | 안티-센스 올리고뉴클레오티드 전달을 위한 지질 나노입자 제형 |
| AU2024206116A1 (en) * | 2023-01-06 | 2025-07-10 | Arrowhead Pharmaceuticals, Inc. | Lipid conjugates for the delivery of therapeutic agents to adipose tissue |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| CN1981044B (zh) * | 2004-06-07 | 2010-05-05 | 普洛体维生物治疗公司 | 包封干扰rna的脂质 |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| US9005654B2 (en) | 2005-07-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
| EP3192788A1 (en) | 2006-10-03 | 2017-07-19 | Arbutus Biopharma Corporation | Lipid containing formulations |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| AU2009238175C1 (en) * | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| WO2010054384A1 (en) | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Lipids and compositions for the delivery of therapeutics |
| HUE037082T2 (hu) * | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Új lipidek és készítmények terápiás hatóanyagok szállítására |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| KR20180094137A (ko) | 2009-05-05 | 2018-08-22 | 알닐람 파마슈티칼스 인코포레이티드 | 지질 조성물 |
| MX342785B (es) * | 2009-06-10 | 2016-10-12 | Alnylam Pharmaceuticals Inc | Formulacion mejorada de lipido. |
| EP2506879A4 (en) | 2009-12-01 | 2014-03-19 | Protiva Biotherapeutics Inc | PREPARATIONS OF SNALP CONTAINING ANTIOXIDANTS |
| US20110313017A1 (en) * | 2010-01-13 | 2011-12-22 | Protiva Biotherapeutics, Inc. | Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates |
| SG186085A1 (en) | 2010-06-03 | 2013-01-30 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| EP2788006B1 (en) * | 2011-12-07 | 2026-01-07 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| EP2788316B1 (en) | 2011-12-07 | 2019-04-24 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| WO2013116126A1 (en) * | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| AU2013249548A1 (en) * | 2012-04-19 | 2014-11-06 | Sirna Therapeutics, Inc. | Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| US9687448B2 (en) * | 2012-12-07 | 2017-06-27 | Alnylam Pharmaceuticals, Inc. | Nucleic acid lipid particle formulations |
| WO2015011633A1 (en) * | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| EP4019506A1 (en) * | 2013-12-19 | 2022-06-29 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| EP4286012A3 (en) * | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| ES3046484T3 (en) * | 2018-10-01 | 2025-12-02 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
-
2019
- 2019-09-27 ES ES23157471T patent/ES3046484T3/es active Active
- 2019-09-27 CN CN201980077559.5A patent/CN113164379B/zh active Active
- 2019-09-27 DK DK19789841.4T patent/DK3860561T3/da active
- 2019-09-27 EP EP25196729.5A patent/EP4635481A3/en active Pending
- 2019-09-27 JP JP2021542068A patent/JP7387745B2/ja active Active
- 2019-09-27 CN CN202410415224.2A patent/CN118307422A/zh active Pending
- 2019-09-27 DK DK23157471.6T patent/DK4218722T3/da active
- 2019-09-27 US US17/250,952 patent/US20220370356A1/en active Pending
- 2019-09-27 CA CA3114435A patent/CA3114435A1/en active Pending
- 2019-09-27 AU AU2019351809A patent/AU2019351809C1/en active Active
- 2019-09-27 KR KR1020257040845A patent/KR20260003834A/ko active Pending
- 2019-09-27 KR KR1020217013284A patent/KR102900877B1/ko active Active
- 2019-09-27 EP EP23157471.6A patent/EP4218722B1/en active Active
- 2019-09-27 ES ES19789841T patent/ES2951836T3/es active Active
- 2019-09-27 WO PCT/US2019/053617 patent/WO2020072324A1/en not_active Ceased
- 2019-09-27 EP EP19789841.4A patent/EP3860561B1/en active Active
-
2023
- 2023-11-14 JP JP2023193747A patent/JP7747712B2/ja active Active
-
2025
- 2025-07-24 AU AU2025208491A patent/AU2025208491A1/en active Pending
- 2025-09-18 JP JP2025155219A patent/JP2026009116A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020072324A5 (https=) | ||
| JP2022508511A5 (https=) | ||
| CA2891911C (en) | Improved nucleic acid lipid particle formulations | |
| JP5475753B2 (ja) | 核酸送達用の脂質製剤 | |
| EP3201338B1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| JP4951338B2 (ja) | 脂質に封入された干渉ｒｎａ | |
| US9701623B2 (en) | Di-aliphatic substituted pegylated lipids | |
| US9415109B2 (en) | Stable non-aggregating nucleic acid lipid particle formulations | |
| CN102281899B (zh) | 用于递送治疗剂的脂质和组合物 | |
| JP2017536092A5 (https=) | ||
| EP2416652B1 (en) | Methods of delivering oligonucleotides to immune cells | |
| JP6592458B2 (ja) | カチオン性脂質 | |
| JP2015500835A5 (https=) | ||
| AU2016210739A1 (en) | Biodegradable lipids for the delivery of active agents | |
| WO2020132196A1 (en) | Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same | |
| JP2011516094A5 (https=) | ||
| JP2011507534A5 (https=) | ||
| JP2022000479A (ja) | インフュージョンリアクションを改善するための方法 | |
| AU2022262355A1 (en) | Tissue-specific nucleic acid delivery by mixed cationic lipid particles | |
| JP7832717B2 (ja) | 硫化物を含むイオン化可能な脂質、及びこれを含む脂質ナノ粒子 | |
| TW201919653A (zh) | 用於治療ｂ型肝炎之治療組合物及方法 | |
| CN110022895A (zh) | 用于治疗乙型肝炎的治疗组合物和方法 | |
| US20220184113A1 (en) | RATIONALLY DESIGNED ANTIVIRAL COMPOUNDS THAT INHIBIT SARS-CoV-2 AND THEIR METHODS OF USE THEREOF | |
| EP4047094A1 (en) | Peptide-nucleic acid complex having blood-brain barrier penetration ability and composition comprising same | |
| WO2025256540A1 (en) | Compositions and method for targeted gene delivery |